MRI-based parameters and clinical risk factors to predict lymph node metastasis in patients with ypT0 rectal cancer after neoadjuvant chemoradiotherapy

被引:0
作者
Wang, Yangyang [1 ,2 ]
Wang, Xiaojie [2 ]
Huang, Shenghui [2 ]
Chen, Jinhua [3 ]
Huang, Ying [2 ]
机构
[1] Shandong First Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Tai An, Peoples R China
[2] Fujian Med Univ, Union Hosp, Dept Colorectal Surg, Fuzhou, Fujian, Peoples R China
[3] Fujian Med Univ, Union Hosp, Follow Up Ctr, Fuzhou, Fujian, Peoples R China
关键词
clinical complete remission; lymph node metastasis; neoadjuvant chemoradiotherapy; rectal-preserving strategy; LOCAL EXCISION; ORGAN PRESERVATION; TUMOR RESPONSE; OPEN-LABEL; FOLLOW-UP; CHEMORADIATION; OUTCOMES; MULTICENTER; ANEMIA; SIZE;
D O I
10.1111/ans.18876
中图分类号
R61 [外科手术学];
学科分类号
摘要
Backgrounds: The aim of this study was to assess the significant risk factors that predict lymph node metastasis in ypT0 patients with locally advanced rectal cancer following chemoradiotherapy (CRT). Additionally, the study aimed to identify high-risk groups who would not be suitable candidates for a rectal-preserving strategy, despite achieving a complete tumour response.Methods: Between 2013 and 2021, 226 ypT0 patients with stages II/III rectal cancer underwent CRT and radical surgery were enrolled. Two groups of patients were evaluated: those with lymph nodes metastasis and those without. The selection of variables for multivariable logistic regression was conducted through bivariate logistic regression analysis. Furthermore, the determination of optimal cutoff values for risk factors was achieved using ROC curve analysis.Results: Nearly 8% (18/226) of patients with ypT0 had positive lymph nodes (LN) on final pathology. Four variables resulted as being independent factors of LN metastasis: pre-CRT tumour movability (OR = 8.618, P = 0.003), pre-CRT maximal LN size (OR = 28.474, P = 0.004), post-CRT tumour vertical length (OR = 1.492, P = 0.050), post-CRT anaemia (OR = 10.288, P = 0.001). The optimal cutoff point of pre-CRT maximal LN size and post-CRT tumour vertical length was 7.50 mm and 3.05 cm, respectively.Conclusion: The prevalence of lymph node metastasis remains at 8% among patients who achieve pathological complete regression of the primary tumour. In instances where patients are considered appropriate candidates for a rectal-preserving strategy after clinical complete remission, careful consideration should be given to the selection of this strategy if specific risk factors are present. These risk factors encompass a maximal LN size surpassing 7.50 mm prior to CRT, a fixed tumour prior to CRT, a tumour vertical length exceeding 3.05 cm after CRT, and the existence of anaemia subsequent to CRT.
引用
收藏
页码:1127 / 1132
页数:6
相关论文
共 50 条
[21]   Prognostic Value of the Distribution of Lymph Node Metastasis in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy [J].
Chen, Bin ;
Liu, Xing ;
Zhang, Yiyi ;
Zhuang, Jinfu ;
Peng, Yong ;
Wang, Ye ;
Wu, Yong ;
Li, Shoufeng ;
Yang, Yuanfeng ;
Guan, Guoxian .
FRONTIERS IN SURGERY, 2021, 8
[22]   Exploring the possibility of omitting axillary surgery in patients with clinical node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy [J].
Shigematsu, Hideo ;
Takaya, Momoko ;
Suzuki, Kanako ;
Fujimoto, Mutsumi ;
Ikejiri, Haruka ;
Amioka, Ai ;
Hiraoka, Emiko ;
Sasada, Shinsuke ;
Arihiro, Koji ;
Okada, Morihito .
BREAST CANCER RESEARCH AND TREATMENT, 2025, 212 (01) :47-56
[23]   MRI-based radiomics to predict neoadjuvant chemoradiotherapy outcomes in locally advanced rectal cancer: A multicenter study [J].
Xiang, Yirong ;
Li, Shuai ;
Wang, Hongzhi ;
Song, Maxiaowei ;
Hu, Ke ;
Wang, Fengwei ;
Wang, Zhi ;
Niu, Zhiyong ;
Liu, Jin ;
Cai, Yong ;
Li, Yongheng ;
Zhu, Xianggao ;
Geng, Jianhao ;
Zhang, Yangzi ;
Teng, Huajing ;
Wang, Weihu .
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2023, 38 :175-182
[24]   In vivo lymph node mapping and pattern of metastasis spread in locally advanced mid/low rectal cancer after neoadjuvant chemoradiotherapy [J].
Farinella, E. ;
Vigano, L. ;
Fava, M. C. ;
Mineccia, M. ;
Bertolino, F. ;
Capussotti, L. .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2013, 28 (11) :1523-1529
[25]   A prospective study on using shear wave elastography to predict the ypT0 stage of rectal cancer after neoadjuvant therapy: a new support for the watch-and-wait approach? [J].
Liu, Mengjia ;
Cui, Ningyi ;
Sun, Chao ;
Gong, Xuantong ;
Wang, Bo ;
Yang, Di ;
Wang, Yong .
FRONTIERS IN MOLECULAR BIOSCIENCES, 2024, 11
[26]   Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Single-Center Experience and Literature Review [J].
Kim, Min Chul ;
Oh, Jae Hwan .
ANNALS OF COLOPROCTOLOGY, 2021, 37 (06) :382-394
[27]   The ypT may better predict the efficacy of neoadjuvant chemoradiotherapy than tumor regression grade in locally advanced rectal cancer patients diagnosed ypT1-4N0 [J].
Cui, Yujun ;
Liu, Xinzhi ;
Li, Shuai ;
Wang, Hongzhi ;
Xiang, Yirong ;
Zhang, Yangzi ;
Song, Maxiaowei ;
Geng, Jianhao ;
Liu, Zhiyan ;
Teng, Huajing ;
Zhu, Xianggao ;
Cai, Yong ;
Li, Yongheng ;
Wang, Weihu .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (04) :1012-1021
[28]   Multiparametric MRI-based Radiomics approaches on predicting response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer [J].
Cheng, Yuan ;
Luo, Yahong ;
Hu, Yue ;
Zhang, Zhaohe ;
Wang, Xingling ;
Yu, Qing ;
Liu, Guanyu ;
Cui, Enuo ;
Yu, Tao ;
Jiang, Xiran .
ABDOMINAL RADIOLOGY, 2021, 46 (11) :5072-5085
[29]   Prediction of Response to Neoadjuvant Chemoradiotherapy by MRI-Based Machine Learning Texture Analysis in Rectal Cancer Patients [J].
Shayesteh, Sajad P. ;
Alikhassi, Afsaneh ;
Farhan, Farshid ;
Gahletaki, Reza ;
Soltanabadi, Masume ;
Haddad, Peiman ;
Bitarafan-Rajabi, Ahmad .
JOURNAL OF GASTROINTESTINAL CANCER, 2020, 51 (02) :601-609
[30]   Prognostic value of residual lymph node status in patients with pathological T0 rectal cancer after neoadjuvant therapy [J].
Luo, Dakui ;
Wang, Zhen ;
Yang, Yufei ;
Li, Qingguo ;
Li, Xinxiang .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18